Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

Impact · against what's priced in

Cellectis is pivoting to in vivo gene editing to extend its cash runway into H2 2028, though this comes at the cost of abandoning its lead CAR T-cell candidates. The market will weigh the loss of the B-ALL and NHL assets against the reduced immediate dilution risk and the potential of the new metabolic disease pipeline.

CLLS−0.10

No priced-in read yet